July 14, 2023
Clinical Outcomes
CE Activities

Intended Audience: This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.

Credit Available: Up to 1.5 credit hours available for nurses (ANCC), pharmacists (ACPE), and physicians (AMA PRA Category 1 Credit™)

Expiration Date:  October 31, 2024

Click Here to Begin!

Educational Objectives
After completing this activity, the participant should be better able to:

  • Assess clinical evidence and professional society guidelines for CGM systems in patients with type 1 or type 2 diabetes
  • Characterize the impact of rtCGM on clinical measures of diabetes care
  • Implement medical and pharmacy benefit design strategies to support appropriate access to rtCGM and develop evidence-based clinical criteria

Expert Faculty

Matthew D. Harman, PharmD, MPH
VP, Clinical Solutions, Employers Health

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP
Endocrine Clinical Pharmacy Specialist, Co-Director, Endocrine Disorders in Pregnancy
Cleveland Clinic Endocrinology & Metabolism Institute

Gary A. Puckrein, PhD
President and Chief Executive Officer, National Minority Quality Forum

Drake Reiter, PharmD
Advisor, Pharmacy Product & Trend, Priority Health

Jointly provided by Impact Education, LLC, and Medical Education Resources.
This activity is supported by an independent educational grant from Dexcom, Inc.

Share:

July 12, 2023
CGM Technology and Digital Health
Clinical Outcomes
CGM Innovations / Webinar / Archive
Share:

June 20, 2023
Clinical Outcomes
Article / Publication

Prescribing of CGM in clinical practice and payer coverage criteria have expanded considering the wealth of evidence and expert recommendations supporting more widespread use. As the body of evidence continues to grow, a new supplement in Diabetes Technology & Therapeutics offers insights from leading clinicians on the latest findings and practical application of CGM. The supplement highlights real-world evidence and the unique role of CGM in the management of hypoglycemia and enhancing behavior modification among users of the technology. Special consideration is given to the economic impact of CGM and access issues that may be of particular interest to payer and managed care decision makers.   

The articles included:

Past, Present, and Future of Continuous Glucose Monitors Satish K. Garg

Continuous Glucose Monitoring Impact and Implications of Real-World Evidence: Past, Present and Future James R. Gavin III and Clifford J. Bailey

What Role Might There Be for Continuous Glucose Monitoring in the Assessment of Diabetes Risk? Eden Miller, William H. Polonsky and Kevin Miller

Practical Application of Continuous Glucose Monitoring in Clinical Practice: Case Studies Jeff Unger and Denise R. Franco

Advancements in Diabetes Technology Are Outpacing the Evidence Michael Rickson, Eugene E. Wright Jr., Anila Bindal and Laith Ghonim

One Size Fits All Versus Individualized Medicine in Type 1 Diabetes Management L. Kurt Midyett

Is Continuous Glucose Monitoring a Tool, an Intervention, or Both? Eugene E. Wright Jr. and Savitha Subramanian

Continuous Glucose Monitoring Use in Older Adults for Optimal Diabetes Management Medha N. Munshi

Personalized Glycated Hemoglobin in Diabetes Management: Closing the Gap with Glucose Management Indicator Timothy C. Dunn, Yongjin Xu, Richard M. Bergenstal, Watru Ogawa and Ramzi A. Ajjan

Prevalence, Cost, and Burden of Diabetic Ketoacidosis Naunihal Virdi, Yeesha Poon, Richard Abaniel and Richard M. Bergenstal

Share:

June 19, 2023
Clinical Outcomes
Coverage and Benefit Design
Article / Publication
Learn More
Share:

June 12, 2023
CGM Technology and Digital Health
Article / Publication
Learn More
Share:

June 8, 2023
Coverage and Benefit Design
Infographic

Share:

June 8, 2023
Clinical Outcomes
Article / Publication

HbA1c has been a mainstay for assessing glycemic management for the better part of 40 years, largely due to its robust correlation with diabetic vascular complications as demonstrated in the Diabetes Control and Complications Trial (DCCT). As CGM becomes more firmly established as standard of care, there is now a growing body of literature showing that TIR also is strongly associated with chronic complications. Dr. Roy W. Beck recently reviewed this evidence in light of a post hoc analysis of the DEVOTE trial by Bergenstal et al. Managed care and payer decision makers will find this expert commentary useful as it concisely summarizes the data demonstrating the validity of TIR as a clinical measure in diabetes care.  

Beck RW. The Association of Time in Range and Diabetic Complications: The Evidence Is Strong. Diabetes Technol Ther. 2023;25:375-377. doi: 10.1089/dia.2023.0141. 

Learn More
Share:

June 6, 2023
Clinical Outcomes
Infographic
Learn More
Share:

June 1, 2023
Population Health
Article / Publication

Despite Medicare making strides toward improving access with expanded coverage criteria in recent years, experts in the field of endocrinology are speaking out on the importance of reaching underserved populations with the “potentially life-changing benefits” of CGM technology. In addition to expanded coverage eligibility, Richard M. Bergenstal, MD, noted that access to CGM must be simplified by making the technology more readily available in clinic and community settings. To support these efforts, Irl B. Hirsch, MD, called on the role of patient and provider education for driving appropriate uptake and utilization. Managed care and payer professionals will find these expert insights valuable for addressing disparities in diabetes care and outcomes among members affected by SDOH. 

Learn More
Share:

May 29, 2023
Clinical Outcomes
Article / Publication
Learn More
Share: